Literature DB >> 11865327

Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels.

N N Lermontova1, A E Redkozubov, E F Shevtsova, T P Serkova, E G Kireeva, S O Bachurin.   

Abstract

Dimebon, a Russian-made drug, inhibited toxic effects of beta -amyloid on cultured neurons. Excessive accumulation of beta-amyloid in the brain is characteristic of Alzheimer dementias. Antialzheimer preparations tacrine and dimebon improve survival of cerebellar granule cells during long-term incubation with Abeta25-35, the neurotoxic fragment of beta-amyloid. Both preparations can block potential-dependent Ca(2+) entry into neurons by about 20%, which is explained by their selective action on L-type Ca(2+) channels. It was assumed that the neuroprotective effect of dimebon and tacrine against Abeta25-35 partially depends on inhibition of potential-dependent Ca(2+) entry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11865327     DOI: 10.1023/a:1017972709652

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  39 in total

Review 1.  Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.

Authors:  Magali Dumont; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

3.  The rise and fall of Dimebon.

Authors:  Ilya Bezprozvanny
Journal:  Drug News Perspect       Date:  2010-10

Review 4.  Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?

Authors:  Cornelis J Van der Schyf; Werner J Geldenhuys
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 5.  An update on treatment and prevention strategies for Alzheimer's disease.

Authors:  Judith Neugroschl; Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

Review 6.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

Review 7.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 8.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

9.  Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.

Authors:  Prashant R Bharadwaj; Giuseppe Verdile; Renae K Barr; Veer Gupta; John W Steele; M Lenard Lachenmayer; Zhenyu Yue; Michelle E Ehrlich; Gregory Petsko; Shulin Ju; Dagmar Ringe; Sonia E Sankovich; Joanne M Caine; Ian G Macreadie; Sam Gandy; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

10.  Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.

Authors:  John W Steele; Soong H Kim; John R Cirrito; Deborah K Verges; Jessica L Restivo; David Westaway; Paul Fraser; Peter St George Hyslop; Mary Sano; Ilya Bezprozvanny; Michelle E Ehrlich; David M Holtzman; Sam Gandy
Journal:  Mol Neurodegener       Date:  2009-12-17       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.